Health Information Search Results
Peer Reviewed Scientific Research Reports.
|<< Prev 20 ||Showing 1 to 5 of 5 Matches||Next 20 >>|
1. Pharmacokinetic profile of tamsulosin OCAS.
Match Strength: 7.212
The tamsulosin oral-controlled absorption system (OCAS(R)) is a new tablet formulation of the alpha(1)-adrenoceptor (alpha(1)-AR) antagonist tamsulosin, which is used for treating lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). The tablet uses the OCAS technology, which was specifically designed to give a more continuous 24-h release of tamsulosin, resulting in a more consistent and continuous 24-h plasma concentration, a lower maximum plasma concentration (C(max)) and an independence of pharmacokinetics (PKs) on food intake. It was expected that the ... Read More »
» Published in BJU Int. 2006 Nov;98 Suppl 2:9-12.
2. Efficacy and safety of tamsulosin OCAS.
Match Strength: 6.572
The efficacy and safety of a new tablet formulation of tamsulosin (the oral-controlled absorption system: OCAS(R)) have been assessed in several clinical trials. In a phase IIb and a phase IIIa trial, the appropriate dose of the tamsulosin tablet for clinical practice was determined. All tested doses of tamsulosin OCAS (0.4, 0.8 and 1.2 mg) improved the lower urinary symptoms (LUTS) of benign prostatic enlargement to a statistically significantly greater extent than placebo, with no differences between the doses. However, treatment with tamsulosin OCAS 0.4 mg was associated with a lower ... Read More »
» Published in BJU Int. 2006 Nov;98 Suppl 2:13-7.
3. The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the emergency department.
Match Strength: 3.581
The management of an agitated, abusive or violent patient is a common and challenging problem in Emergency Medicine. Priorities include measures to ensure the safety of the patient and the emergency staff, including provision of physical restraint of the patient and evaluation for correctable medical causes of such behavior. Medications used in the treatment of such patients include benzodiazepines and antipsychotic agents. The newer atypical antipsychotic agents seem to provide a safe and effective treatment for such patients. The atypical antipsychotic agents may have fewer short-term side ... Read More »
» Published in J Emerg Med. 2006 Oct;31(3):317-24.
4. Stability of nevirapine suspension in prefilled oral syringes used for reduction of mother-to-child HIV transmission.
Match Strength: 3.097
OBJECTIVE: To reduce mother-to-child transmission (MTCT) of HIV, we assessed the stability of nevirapine suspension in an oral dosing syringe over a range of storage conditions. DESIGN: A mother-to-child transmission dosing kit, containing a maternal nevirapine tablet and infant nevirapine suspension in an oral syringe that can be dispensed to the pregnant woman to use at delivery. However, the manufacturer only packages nevirapine in 240 mL, multidose containers and there are no published stability data for nevirapine suspension repackaged in an oral syringe. METHODS: Nevirapine suspension 6 ... Read More »
» Published in J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):373-5.
5. Corticosteroids therapy in the management of infantile cutaneous hemangiomas.
Match Strength: 2.535
Objective: To determine the effectiveness of systemic and intra-lesional corticosteroids, in the management of infantile cutaneous hemangiomas and to compare the results with untreated lesions. Design: Randomized controlled trial. Place and Duration of Study: Surgical Unit B of National Institute of Child Health, Karachi, from January 2001 to January 2003. Patients and Methods: A total of 75 cases with cutaneous hemangiomas were included in the study. Three groups of 25 patients each were made by allocating first patient to control group, every second patient to oral steroid group and every ... Read More »
» Published in J Coll Physicians Surg Pak. 2006 Oct;16(10):662-5.
|<< Prev 20 ||Showing results 1 to 5 of 5||Next 20 >>|
* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.